Tezepelumab

SAN FRANCISCO — About half of patients with asthma on tezepelumab had discontinued their daily maintenance oral corticosteroid doses by 52 weeks, according to an abstract presented at the American Thoracic Society International Conference.

Patients with small airways dysfunction experienced clinically and statistically significant improvements in peripheral resistance and compliance with tezepelumab, according to a study published in Annals of Allergy, Asthma & Immunology.

SAN DIEGO — Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and 2023, according to a poster presented here.

SAN DIEGO — Patients with severe asthma required fewer steroid bursts with tezepelumab-ekko, according to a poster presented at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization Joint Congress.

SAN DIEGO — Patients with chronic rhinosinusitis with nasal polyps saw improvements across all endpoints with tezepelumab, according to an abstract presented here.

SAN DIEGO — Across six asthma biologics, adherence differed by the therapy given and was often low or irregular based on three adherence measures, according to a presentation here.

BOSTON — Patients with obesity and asthma may see reductions in exacerbations with biologic treatment, according to a presentation at the CHEST Annual Meeting.

Healio Pulmonology has compiled the top news on COPD posted in 2024.

Patients with severe chronic rhinosinusitis with nasal polyps experienced significant improvements in their symptoms with tezepelumab-ekko compared with placebo, according to a press release from Amgen and AstraZeneca.

PHILADELPHIA — The current biologics for patients with COPD include anti-IL-5 therapies, dupilumab, tezepelumab and anti-IL-33 therapies, according to a presentation at the 2024 GOLD COPD International Conference.